Fig. 2From: Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migrainePain freedom at 30, 60, 90, and 120 min postdosea,b. Legend: SC, subcutaneous. aMean (SD) predose pain intensity average was 2.00 (.58). b1 subject randomized to 6 mg only treated 1 attackBack to article page